| February 20, 2012: | Quiet period prior to the annual report begins |
| March 19, 2012: | Annual report for 2011 |
| April 17, 2012: | Shareholders meeting |
| May 11, 2012: | Quiet period prior to the interim report begins |
| May 25, 2012: | Interim report – 3 months 2012 |
| August 9, 2012: | Quiet period prior to the interim report begins |
| August 23, 2012: | Interim report – 6 months 2012 |
| November 6, 2012: | Quiet period prior to the interim report begins |
| November 20, 2012: | Interim report – 9 months 2012 |
About BioPorto
BioPorto develops and markets antibodies and antibody-based products, including assays for the diagnosis of diseases—for the benefit of individual patients and the effectiveness of the healthcare sector. The company has inter alia developed a method (NGAL) for the diagnosis and monitoring of acute renal injury. Within the focus areas of the company, it is BioPorto's strategy to develop new methods that can be protected by patents and used extensively in the diagnosis of a number of diseases. BioPorto was established in 2000 and has approx. 30 employees. The Company's shares are listed on the NASDAQ OMX in Copenhagen (symbol BIOPOR).
Further information:
Frank Harder, CFO
Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com
